ADP-TILIL7

N/A

Report date: 2026/04/17 10:36:22

Base Information

Drug NameADP-TILIL7
Drug Alias NameADP-TILIL7
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Tumor Infiltrating Lymphocytes
Mechanisms of ActionInterleukin-7 stimulantsT lymphocyte replacements
TargetsInterleukin-7
Therapy Area/IndicationsMelanoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesDenmark
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesAdaptimmune Therapeutics Plc
China Registration ClassN/A

Develop Information

Active CompaniesAdaptimmune LlcAdaptimmune Therapeutics Plc
Inactive CompaniesN/A
Active IndicationsMelanoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A